Background. Several series predicting the prognosis of staphylococcal prosthetic joint infection (PJI) managed with debridement, antibiotics, and implant retention (DAIR) have been published, but some of their conclusions are controversial. At present, little is known regarding the efficacy of the different antibiotics that are used or their ability to eliminate methicillin-resistant S. aureus (MRSA) infection.
Staphylococcus aureus is the microorganism most frequently responsible for prosthetic joint infection (PJI), especially in acute cases where debridement, antibiotics, and implant retention (DAIR) may be attempted [1] [2] [3] . This approach may cure the patient, reduce costs, and prevent the loss of bone stock and the need for additional operations [3] [4] [5] [6] .
An increased risk of joint failure has been associated with S. aureus infection [3, 7, 8] , as well as with delay in administration of debridement, older age of the implant, prosthesis loosening, or the presence of a sinus tract [1, 2, 9, 10] . However, clinical series of PJI by S. aureus addressing the efficacy of DAIR usually include small samples, frequently in combination with coagulase-negative Staphylococci (CNS) [4, 11] . Moreover, the efficacy of DAIR may have improved with the introduction of rifampin during the last decade [12] .
Infection by methicillin-resistant S. aureus (MRSA) could worsen the prognosis [13] [14] [15] [16] [17] [18] , due to the more limited range of antibiotics available [19] . However, this poorer prognosis of MRSA-PJI is controversial because case series include small numbers of MRSA infections, and the outcome of some of these patients was improved when treated with rifampin [8, 9, 20] .
We present a large, multicenter series of cases of PJI by S. aureus treated with DAIR. The aim of this study was to assess the efficacy of DAIR, to identify factors predicting failure, and to establish the impact of MRSA and the use of rifampin combinations on prognosis.
METHODS

Setting and Patients
A retrospective, observational study was carried out in 17 hospitals in Spain, in the framework of the Spanish Network for Research in Infectious Diseases between [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] . All cases of PJI originally caused by S. aureus and managed with DAIR were included, regardless of the age of the implant at the time of symptom onset. Patients with an unstable prosthesis or with surrounding soft tissues badly damaged did not undergo DAIR. Polymicrobial infections were also included. Cases where S. aureus did not cause the original PJI but participated later as a superinfecting microorganism were excluded. The identification of cases with S. aureus PJI was made from previously registered databases of PJI or from the general archives in each hospital. The decision to undergo DAIR and antimicrobial therapy was made by the attending medical team, based upon current recommendations [2, 5] .
PJI by S. aureus was defined by ≥2 surgical, joint-aspirated or blood cultures yielding S. aureus, or by 1 such positive culture plus the presence of typical clinical symptoms and signs, such as joint pain, erythema and other inflammatory signs, or the presence of a sinus tract or purulence around the prosthesis during surgery [9] . Microorganisms were identified according to standard criteria [21] after samples had been seeded in liquid (thioglycolate) and solid media (5% sheep blood, chocolate, and MacConkey agar) and incubated for at least 7 days. PJI was subsequently classified as post-surgical or hematogenous, being the latter characterized by an acute clinical presentation associated with documented or suspected bloodstream infection [1, 2] .
Data on clinical presentation, risk factors for PJI, and baseline characteristics were recorded. Rheumatoid arthritis was defined by diagnostic criteria [22] . Chronic renal impairment was defined as a level of creatinine>150 μmol/L. Diagnostic prosthesis radiography was considered to be abnormal if there were signs of loosening or infection. Information regarding surgical treatment, exchange of removable pieces of the prosthesis (in at least 1 debridement), and type and duration of antimicrobials were also recorded. A composite variable based upon Zimmerli's algorithm [2] was considered if the patient was submitted to debridement within the first 21 days after symptom onset, plus if the prosthesis radiography was normal, plus if the prosthesis had been placed less than 3 months after the beginning of symptoms (for post-surgical cases).
All information was introduced in a specifically designed Microsoft Access database. All cases were critically reviewed by 2 authors ( J.L-T. & J.A.). Any controversy or contradiction found was double-checked by the investigator at each hospital.
Clinical and Surgical Management
DAIR management has been described elsewhere [8] . Standard procedure consists of checking the solid fixation of the prosthesis, and when possible, the prosthetic exchangeable components are removed. After debridement, intravenous antibiotics of wide antimicrobial-spectrum are administered. Once the antimicrobial susceptibility was available, antibiotics were adjusted according to current guidelines. The intravenous route was maintained for a variable period depending on each hospital protocol, usually followed by oral antibiotics also for a variable time.
DAIR was considered to initiate with the first debridement procedure. Cases initially treated with antibiotics for >7 days without evident signs of infection during debridement, and if samples taken yielded no microorganisms, were not included in this analysis.
Outcome and Follow-Up
Failure was defined as: a) death related to the infection; b) prosthesis removal within 2 years of the beginning of treatment, for any cause, or after 2 years due to persistence/relapse of the staphylococcal infection and/or caused by other superinfecting microorganisms; c) the need for extra debridements 30 days after the first; or d) the need for extra courses of antibiotic after the initial scheduled treatment, including longterm antibiotic suppressive therapy (AST). Although these last 2 criteria (extra debridements and AST in patients with a foreseeable bad outcome) are not well established reasons for failure, they were assumed as a consensus among the investigators.
We performed an Overall Failure analysis. In order to evaluate the impact of antimicrobial therapy, we took into account failure dynamics and also performed a separate analysis of parameters predicting failure depending on the moment when it occurred:
• Early Failure: failure within 30 days of debridement surgery.
• Late Failure: failure while the patient was still under antimicrobial therapy, but occurring after the first 30 days after debridement.
• Failure After Therapy: failure after the end of antimicrobial therapy.
Statistical Analysis
Comparative The length of antibiotic therapy could be shortened in cases failing prematurely and would not actually be the cause of failure but its consequence, and therefore, the antimicrobial therapy parameters were only analyzed when the comparison groups had had the same possibilities of receiving antibiotics. For this reason, this influence was not analyzed in Overall and Early Failures. The influence of antibiotics administered during the first 30 days was analyzed for Late Failure and Failure After Therapy, and the influence of the whole length of treatment was analyzed for Failure After Therapy.
Data were analyzed using SPSS (Statistical Package for the Social Sciences) software (version 15.0). All analyses were 2-tailed, and a P value < .05 was considered statistically significant.
RESULTS
Description of the Series
A total of 561 cases of PJI by S. aureus were diagnosed. Among them, 349 (62%) were managed with DAIR. Four (1%) patients were removed from this set due to a significant lack of data. Therefore, our analysis was carried out with 345 episodes occurring in 342 patients, of whom 140 (41%) were men, with a median age of 73 years (range 27-95). MRSA caused 81 (23%) episodes.
Infection was polymicrobial in 64 cases (19%). The most frequent microorganisms accompanying S. aureus were Enterobacteriaceae (of 33 cases, 11 were Proteus spp and 9 were E. coli), followed by CNS (10 isolates), Pseudomonas spp (8 isolates), Enterococci (7 isolates) and Streptococci (6 isolates).
There were 78 (23%) post-surgical cases with symptoms that began more than 30 days after the placement of the prosthesis (median of 64 days, interquartile range [IQR]: 35-184). In 50 (64%) cases, symptoms began within the initial 90 days.
All patients received appropriate initial empirical antibiotic therapy, and further specific antibiotic regimens were doublechecked with microbiological susceptibility tests.
Hematogenous Versus Post-Surgical PJI Table 1 shows a comparative analysis between post-surgical and hematogenous infections. The latter occurred more frequently among immunosuppressed patients, was often located in knee prostheses, and was monomicrobial, being caused by methicillin-susceptible S. aureus (MSSA) in 88% of cases. Hematogenous infections presented a more inflammatory clinical picture and a poorer prognosis, in spite of undergoing earlier debridement. Table 1 also presents a comparative analysis of MRSA and MSSA cases. MRSA-PJIs were most often suppurative and post-surgical hip-PJIs, occurring in older patients with more frequent comorbidity, especially chronic renal impairment. However, when hematogenous infections were excluded, no significant differences in the clinical presentation were observed (data not shown).
MRSA-Versus MSSA-PJI
The surgical approach was alike in the MRSA and MSSA groups. Also, the length of antimicrobial therapy was similar in patients who completed the scheduled treatment without failing (94 days [IQR 61-162] vs 91 days [IQR 74-120]; P = .922). As expected, there were major differences between MRSA and MSSA cases regarding the specific antibiotics administered (Table 2 ). However, in both scenarios, rifampin was extensively used and to a similar extent: 303 (88%) patients were treated at some point with rifampin. Among patients not presenting Early Failure, 222 (76%) had been treated for ≥2 weeks during the first month after debridement, and among the patients who did not fail during the scheduled treatment, 189 (80%) had received rifampin for ≥4 weeks. In addition, rifampin treatment was initiated very early [delay of 0 days after debridement (IQR: 0-5)]. In the case of MSSA infections, combinations of rifampin were mostly made with beta-lactams (13%) or quinolones (75%, mainly levofloxacin), while MRSA cases were treated with combinations of rifampin and glycopeptides (18%, namely vancomycin), cotrimoxazole (46%), linezolid (24%), or clindamycin (10%).
Outcome
Seventeen patients (5%) were lost to follow-up and/or had an unknown outcome. Among the 328 remaining patients, failure was documented in 146 (45%): there were 10 (7%) related deaths; 114 (78%) patients required the removal of the prosthesis to control the infection (in 81% due to staphylococcal persistence or relapse); 14 (10%) patients needed further courses of antibiotics and/or debridements more than 30 days after the initial one; and 8 (5%) patients needed long-term AST.
Among 60 cases treated with rifampin and finally presenting staphylococcal persistence or relapse, development of resistance to this antibiotic was observed in 6 (10%). Three were MRSA-PJIs: 2 received vancomycin and 1 cotrimoxazole; and 3 were MSSA-PJI: 1 was treated with cotrimoxazole and 2 with fluoroquinolones (1 also developed resistance to levofloxacin). Among polymicrobial infections, no patient failed exclusively due to persistence or relapse of the initially accompanying microorganisms other than S. aureus. The median survival time without failure was 1257 days (95% confidence interval: 361-2153). The rate of failure was not related with any particular period of the study. Figure 1A illustrates that the likelihood of failure was much higher during the first few weeks after debridement. Among all failures, 42 (29%) occurred within the first 30 days of surgery. Table 3 shows the parameters associated with Early Failure: patients with inflammatory, polymicrobial, and bloodstream infections, rheumatoid arthritis, or male sex were more likely to fail.
Dynamics of Failure
After the initial 30 days, 47 (32%) patients failed while still on therapy (Late Failure). Older immunosuppressed patients with the presence of a sinus tract and MRSA-PJIs were more likely to fail, as well as patients needing ≥2 debridements.
There were 57 (39%) Failures After Therapy. Independent predictors were hematogenous infection, PJI by MSSA, delayed debridement, and the need for ≥2 debridements to control the infection. Table 4 summarizes the parameters related with Overall Failure. Immunosuppression and the degree of complexity of the infection ( polymicrobial, bacteremic, or presenting with high CRP levels) were independent predictors of failure. The need for ≥2 debridements also increased the likelihood of e failure, and the exchange of the polyethylene component was an independent predictor of success. Overall, there were 82 patients (25%) who were managed with DAIR even though they did not accomplish Zimmerli's algorithm [2] . Failure was slightly higher among these patients (52% vs 42%; P = .095) and it presented earlier (920 ± 113 vs 1440 ± 94 days; P = .065).
MRSA Versus MSSA Outcome -Influence of Antimicrobial Therapy Overall, there were similar failure rates for MRSA-and MSSA-PJI (46 vs 44%; P = .778), but with different dynamics ( Figure 1B) . During the antimicrobial treatment and after the first 30 days, MRSA cases were more than twice as likely to fail as MSSA-PJIs. In contrast, after treatment, MSSA cases failed more than MRSA-PJIs (Figure 2 ). This was still observed after excluding hematogenous cases (data not shown).
Patients treated with rifampin during the first 30 days of treatment showed a lower likelihood of Late Failure (Table 3 ). An analysis of post-surgical PJIs, without the influence of hematogenous cases, is presented in Table 5 , which shows that rifampin-based combinations exerted an independent favorable influence.
We were not able to demonstrate the influence of antibiotics administered after the first 30 days. Figure 3 also illustrates that longer treatments were not associated with better outcomes. Finally, post-surgical cases with onset of symptoms more than 90 days after the placement of the prosthesis had a tendency towards a worse outcome (Figure 4 ).
DISCUSSION
In this series of PJI by S. aureus, DAIR was able to save 55% of implants in the long-term. While this percentage is in the middle range of staphylococcal-PJI series managed with DAIR (13-75%) [7-11, 16, 18, 23] , it was low when compared with other recent cohorts using rifampin-based regimens [10, 20, 23] . Our rate of success may have been lowered by a longer delay in the administration of debridement and the inclusion of hematogenous cases and prosthesis placed >90 days before the beginning of symptoms, as well as the criteria we used, such as considering the patients as failures if they underwent long-term AST. However, because this is a multicenter study with a larger sample than previous analyses (n = 21-53), our data may be closest to the real likelihood of healing and retaining a joint prosthesis after staphylococcal PJI [7] [8] [9] [10] [11] 16] . Overall, the treatment of MRSA infections was not less successful than MSSA-PJI. This contrasts with previous reports of MRSA-PJI, which suggested poorer rates of success (16-35%) [11, 13, 16, 17] . Interestingly, most of our MRSA infections were early and extensively treated with rifampin. This antibiotic has been shown to maintain strong antimicrobial activity against clinical and experimental staphylococcal foreign body infections [12, 19, [24] [25] [26] . Indeed, modern series of PJI using rifampin for MRSA infections have shown better results than earlier ones, with success rates of 67%-100% [8, 10, 20] .
Nevertheless, the behavior of MRSA-and MSSA-PJI was not the same: 88% of MRSA failures occurred during the first weeks after debridement while patients were still on therapy; in contrast, half of MSSA failures occurred once the antibiotic was withdrawn. When we excluded hematogenous patients, we again observed these different dynamics in failure, as well as a similar clinical presentation of MRSA-and MSSA-PJI. The surgical approach in the 2 groups was very similar, and so the main difference in treatment between MRSA and MSSA cases was the specific rifampin-based combination used in each group. Although a direct comparison between the specific combinations was not possible, this may suggest that not all treatments with rifampin are the same. The specific combination of quinolones plus rifampin has been considered the treatment of choice of MSSA-PJI [2, 23] . Thus, rifampin combinations for MRSA-PJI did not avoid failure as much as rifampin-fluoroquinolone combinations did among MSSAcases, not failing until the withdrawal of the antibiotics. In addition, the development of resistance to rifampin among failures was less frequent when rifampin was combined with quinolones rather than other antimicrobials.
In our series, the type of antibiotic therapy administered during the first 30 days after debridement had an influence on For the multivariate analysis, variables with a P value < .10 in the univariate analysis were included in a stepwise backward selection process (P-in<.05 and P-out<.10 were used in each step).
Abbreviations: CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; MRSA, methicillin-resistant Staphylococcus aureus; NS, non-significant (P > .10); OR, odds ratio.
Debridement delay, time from onset of symptoms to debridement ( a more than10 days; b days to debridement). c Multivariate analyses do not include polyethylene exchange due to a significant lack of data. the outcome, indicating the importance of the initial antibiotics given just after surgery, when all efforts to remove the inoculum and the biofilm have been made.
Although our analysis was unable to show the influence of the therapy after the first few weeks, this does not mean that the antimicrobial therapy administered after this point was For the multivariate analysis, variables with a P value < .10 in the univariate analysis were included in a stepwise backward selection process (P-in<.05 and P-out<.10 were used in each step).
According to this model, in a non-immunosuppressed patient with a monomicrobial prosthetic joint infection and no bacteremia, CRP less than 100 mg/L and the need for only 1 debridement with exchange of removable pieces, the likelihood of success at 6 months would be 77%, while for a patient with the opposite situation, it would be less than 1%.
Abbreviations: CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; MRSA, methicillin-resistant Staphylococcus aureus; NS, non-significant (P > .10). a Days without failure expressed in mean ± standard deviation.
not important. In this regard, our results should be interpreted cautiously: most of our patients were treated for at least 60 days, meaning that a long course of antibiotics was needed; also, the retrospective nature of our work makes it difficult to compare different schedules. Furthermore, the length of treatment was the physician's choice, and so it is likely that longer therapies were applied in more severe cases, in a similar way as seen in Byren's work, which showed that prolonging therapy could delay relapse but not avoid it [8] .
The literature mentions many other factors influencing the outcome of PJI that possess varying degrees of importance depending on the series. As noted by other authors [10] , we found that the complexity and degree of inflammation of the infection were associated with the prognosis. Patients needing more than 1 debridement were also more likely to fail, probably because they had a more complex and highly inflammatory infection [10] . This inflammatory pattern was more frequent among hematogenous cases, carrying a worse prognosis [27] [28] [29] .
Patients' baseline features and comorbidity also had an impact, especially in subjects under immunosuppressive therapy. Some studies report that revision prostheses have worse outcome than primary implants [8] , but this issue is controversial [9] , and we did not find statistical significance in our analysis.
In addition, because of the multicenter nature of our study, there may have been considerable surgical variability that likely influenced the outcome. We found that exchanging the polyethylene component of the prosthesis reduced the risk of failure by 33%, in spite of incomplete retrospective data.
In Brandt's study [9] , patients delaying their debridement for >2 days had a poorer prognosis. This cutoff has not been confirmed by more recent studies [7, 8, 10] , perhaps due to differences in patient selection or antibiotic management (ie, the addition of rifampin). Also, debridements may be performed earlier in more severe cases (ie, hematogenous infections), which would thus balance the real impact of an early debridement. In our study, we found that the time to debridement from the onset of symptoms was independently associated with prognosis when analyzing patients failing after treatment and also among post-surgical cases.
Recommendations pertaining to the age of the prosthesis at the time of attempting DAIR vary significantly between authors, ranging from less than 4 weeks [1, 3] to less than 90 days [2] . In our analysis, a similar prognosis was observed among these 2 groups of patients.
In summary, we present the largest series of staphylococcal PJIs managed with DAIR and assess the influence of different prognostic factors. A substantial number of patients fail early despite DAIR. Overall, the use of rifampin may contribute to homogenizing the prognosis for MRSA-and MSSA-PJI, although the differences we observed in their outcome may suggest a variable efficacy of the specific rifampin combination used. Further progress in the knowledge of these infections should come from prospective studies.
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Supplementary materials are available at Clinical Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author. Patients with Early Failure were excluded from this analysis. For the multivariate analysis, variables with a P value < .10 in the univariate analysis were included in a stepwise backward selection process (P-in < .05 and P-out < .10 were used in each step, except a , where P-out was <.05).
Notes
Abbreviations: CRP, C-reactive protein; HR (95%CI), hazard ratio (95% confidence interval); MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; NS, non-significant (P > .10). b Time to infection: time from prosthesis placement to the onset of symptoms.
c Debridement delay: time from onset of symptoms to debridement.
d Polyethylene exchange not included in multivariate analysis due to a significant lack of data.
e All antimicrobial data refer to antibiotics received during more than 14 days within the first 30 days after debridement. Figure 4 . Influence of the time from prosthesis placement to the beginning of symptoms among post-surgical cases. Black continuous line: symptoms beginning less than 31 days after the placement of the prosthesis (n = 207; 38% failures). Grey continuous line: symptoms beginning 31 to 90 days after the placement of the prosthesis (n = 46; 41% failures). Black discontinuous line: symptoms beginning more than 90 days after the placement of the prosthesis (n = 26; 62% failures). Log-rank test: P = .052. *Number of patients at risk for failure at the beginning of the period. **Patients failing during the period. ***Number of patients lost to follow-up during the period. Six patients with unknown outcome were excluded from this analysis. 
